Previous 10 | Next 10 |
home / stock / gild / gild articles
On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results fro...
On Thursday, Gilead Sciences Inc (NASDAQ:GILD) announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or meta...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.84% on an annualized basis producing an average annual return...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does that say about Gilead?" says Jim, Senior Direct...
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
2024-06-24 13:00:04 ET Michael Yee from Jefferies issued a price target of $85.00 for GILD on 2024-06-24 10:57:00. The adjusted price target was set to $85.00. At the time of the announcement, GILD was trading at $71.24. The overall price target consensus is at $80.71 wi...